Company intelligence / Profile preview
Small Pharma
London, England, United Kingdomsmallpharma.com ↗
- Ownership
- Private
- Employees
- ~30
- Development stage
- Other
01
Overview
Small Pharma is a clinical-stage biotechnology company developing psychedelic-based treatments for mental health disorders, with its lead candidate SPL026 (N,N-dimethyltryptamine, DMT) having completed a Phase IIa trial demonstrating rapid and durable antidepressant effects in patients with major depressive disorder. The company has also advanced other short-duration psychedelic compounds into early clinical development.
- Therapeutic areas
- Psychiatry
- Modalities
- Small moleculesPsychedelic-assisted therapies (notably DMT and related compounds)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Small Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Small Pharma.